Tesamorelin and ipamorelin both increase your own growth hormone, but they flip different switches. Tesamorelin mimics growth hormone-releasing hormone (GHRH) and has large clinical trials showing a 15–20% reduction in visceral belly fat. Ipamorelin mimics ghrelin and triggers a clean, selective growth hormone pulse that is popular for recovery, sleep, and lean-muscle support.
The short answer: choose tesamorelin if your main goal is losing stubborn abdominal and visceral fat. Choose ipamorelin if your priority is recovery, sleep, and body recomposition. Because they act on different receptors, they also work well together.
The biggest difference is which receptor they activate. Your pituitary gland has two main "on" switches for growth hormone:
GHRH sets how much growth hormone the pituitary is ready to release. Ghrelin-receptor activation acts as a trigger that releases it, while also suppressing somatostatin, the body's growth hormone brake.
That is why the two peptides feel different in practice. Tesamorelin produces a steadier rise in IGF-1 — the hormone behind most of growth hormone's fat-burning and tissue-building effects. Ipamorelin produces a sharp burst of growth hormone that peaks roughly 40 minutes after dosing and fades within a few hours, according to human pharmacokinetic research.
Older ghrelin mimetics such as GHRP-6 and GHRP-2 release growth hormone but also raise cortisol, ACTH, and prolactin, and GHRP-6 in particular causes strong hunger.
Ipamorelin was developed specifically to avoid that. In its original pharmacology study, ipamorelin released growth hormone without significantly raising ACTH or cortisol — even at doses more than 200 times higher than needed for GH release. It also did not affect prolactin, FSH, LH, or TSH. Researchers described it as the first ghrelin-receptor agonist with GH selectivity similar to GHRH itself.
Tesamorelin is selective by design, since the GHRH receptor is dedicated to growth hormone release.
Tesamorelin is the clear winner for belly fat. It is the most studied growth hormone peptide for visceral fat — the deep abdominal fat surrounding organs that drives insulin resistance, high triglycerides, and fatty liver.
In a New England Journal of Medicine trial of 412 adults with excess abdominal fat, 26 weeks of tesamorelin reduced visceral fat by 15.2% while it rose 5% with placebo. Triglycerides fell by 50 mg/dL. A pooled analysis of two phase 3 trials confirmed the results and showed benefits maintained through 52 weeks, with subcutaneous fat largely preserved.
Ipamorelin has no comparable fat-loss trials. Its effect on body composition comes indirectly through repeated growth hormone pulses, better recovery, and improved training capacity. It fits best in a recomposition plan — losing some fat while building lean mass — rather than as a targeted fat-loss tool.
For larger overall weight loss, a GLP-1 medication such as tirzepatide is a different, more powerful category. Compare every option in our guide to the best peptides for fat loss.
Neither peptide is a steroid, and neither builds muscle without training. Both support an anabolic environment by raising growth hormone.
If your goal is muscle growth and recovery, ipamorelin — usually as part of CJC-1295 with ipamorelin — is the more common choice. If your goal is recomposition with a focus on the midsection, tesamorelin has the stronger data. See more options in our guide to the best peptides for muscle growth.
Ipamorelin is the more popular choice for recovery and sleep. Taken before bed, it amplifies the large natural growth hormone pulse that occurs during early deep sleep. Many people report deeper sleep, less soreness, and better recovery between workouts within the first few weeks.
Tesamorelin can support the same overnight growth hormone rhythm but is chosen mainly for its effect on body composition.
For more sleep-focused options, read our guide to the best peptides for sleep.
Tesamorelin has strong liver data. A randomized trial in JAMA found six months of treatment reduced liver fat alongside visceral fat. A later multicenter trial in people with non-alcoholic fatty liver disease showed tesamorelin reduced liver fat by 37% relative to baseline, with 35% of patients reaching a normal liver-fat level versus 4% on placebo.
Ipamorelin has not been studied for liver fat or metabolic markers in the same way. If triglycerides, waist size, or liver fat are part of your goals, tesamorelin is the evidence-based choice.
Tesamorelin has a notable cognitive trial. In 152 adults aged 55–87, 20 weeks of nightly tesamorelin improved executive function in both healthy older adults and those with mild cognitive impairment, while reducing body fat by 7.4%.
Ipamorelin has no equivalent cognitive research, though better sleep often translates into better daytime focus and energy.
Because ipamorelin works through the ghrelin receptor, some people notice a mild increase in appetite, especially early on. It is far less pronounced than with GHRP-6, which is known for strong hunger. Tesamorelin works through a different receptor and does not typically affect appetite.
Ghrelin-receptor activation also increases gut motility. In a phase 2 trial after bowel surgery, ipamorelin was studied specifically for this effect and was well tolerated at the doses tested.
Ipamorelin's effects on sleep and recovery are usually the first thing people notice, often within the first few weeks. Tesamorelin's signature benefit — visceral-fat reduction — builds over months, with the largest measured changes in trials at around six months.
Track waist measurements and body-composition scans rather than scale weight. Losing visceral fat can shrink your waist while the scale barely moves.
Both are generally well tolerated, and both can cause injection-site redness, brief flushing, and mild headache.
Yes — and this is one of the most logical growth hormone stacks. Because tesamorelin activates the GHRH receptor and ipamorelin activates the ghrelin receptor, combining them produces a synergistic effect: the GHRH signal primes the pituitary, the ghrelin signal triggers the release and lowers somatostatin, and the resulting growth hormone pulse is larger than either peptide produces alone.
This is the same principle behind CJC-1295 with ipamorelin. Swapping CJC-1295 for tesamorelin shifts the stack toward visceral-fat reduction and metabolic health.
Bowery Clinic's Form blend is built around this pairing, combining tesamorelin and ipamorelin with AOD-9604 and MOTS-c for body-composition and metabolic goals.
Compare this with pairing tesamorelin and sermorelin, which both hit the same GHRH receptor, in our guide to tesamorelin vs sermorelin.
Both peptides keep your natural feedback loops intact, which is why they are often preferred over synthetic HGH for adults without diagnosed growth hormone deficiency. Learn more in our guide on how to increase growth hormone.
Choose tesamorelin if you:
Choose ipamorelin if you:
Choose both if you want the fat-targeting power of tesamorelin with the amplified growth hormone pulse that a ghrelin mimetic adds.
For fat loss and IGF-1 elevation, yes. Tesamorelin produces a larger and more consistent IGF-1 increase and has far more clinical evidence. Ipamorelin produces a sharp, selective growth hormone pulse that is better suited to recovery and sleep.
Tesamorelin. It is the only one of the two with large randomized trials showing significant visceral-fat reduction — about 15–20% over 6–12 months.
No. Tesamorelin is a GHRH analog. Ipamorelin is a growth hormone secretagogue that works through the ghrelin receptor. They reach the same outcome — more of your own growth hormone — through different pathways.
Yes. Because they act on different receptors, they work synergistically and produce a larger growth hormone pulse together than either does alone.
Ipamorelin is more commonly used for muscle recovery and lean-mass goals, usually alongside a GHRH analog. Tesamorelin improves muscle density and trunk muscle area, particularly in people losing visceral fat.
No. Ipamorelin's main advantage over older GHRPs is that it releases growth hormone without meaningfully raising cortisol, ACTH, or prolactin.
No. Both stimulate your pituitary rather than replacing its output, so your natural feedback loops remain intact.
Both are commonly taken as a small subcutaneous injection at bedtime on an empty stomach, which lines up with the body's largest natural growth hormone pulse during early sleep.
Tesamorelin and ipamorelin both raise your own growth hormone, but through different receptors and for different goals. Tesamorelin is the evidence-backed choice for visceral fat, liver fat, and metabolic health. Ipamorelin is a selective, well-tolerated option for recovery, sleep, and lean mass. Together, they form a complementary stack that targets both pathways at once.
To find out which fits your goals, explore Tesamorelin, CJC-1295 + Ipamorelin, or Form at Bowery Clinic.
